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Introduction
Acute exacerbations are largely responsible for the poor outcomes characterising COPD, the third leading
cause of death globally and associated with a significant disability and socioeconomic burden [1, 2]. Every
year, 22–40% of all people suffering from COPD experience at least one moderate or severe exacerbation,
while 9–16% experience more than one [3, 4]. Exacerbations are associated with an increased risk of
subsequent exacerbations, cardiac events, worse quality of life and an accelerated lung function decline [5].
15% of all severe exacerbations requiring hospitalisation lead to death within 90 days [6]. Thus, it is not
surprising that patients consider exacerbations and hospitalisations due to exacerbations the most
important, burdensome outcomes of COPD [7].
In contrast to the rapidly evolving management of other diseases, such as acute coronary syndrome, the
management of exacerbations remains insufficient, with little advancement for decades; they thus
represent a major, unaddressed global health need [1, 2]. To improve the management and outcomes of
COPD exacerbations, we launched an international, multidisciplinary clinical research network, the
DECODE-NET (DisEntangling Chronic Obstructive pulmonary Disease Exacerbations: The
DECODE-NET clinical trials NETwork), aiming to identify and remedy potential issues delaying the
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development of novel therapeutic approaches, and to conduct high-quality collaborative clinical research
on the management of COPD exacerbations, with a focus on clinical trials. Here, we summarise crucial
gaps in our clinical knowledge as well as the methodological challenges of conducting trials on the
management of COPD exacerbations and how the DECODE-NET aspires to address them.
Knowledge gaps complicating clinical research on COPD exacerbations
Clinical research is complicated by our limited understanding of exacerbations and their underlying
mechanisms. Firstly, COPD exacerbations are still loosely defined as acute episodes characterised by a
deterioration in the respiratory symptoms, in patients with pre-existing COPD [8]. In the absence of
accurate diagnostic biomarkers, diagnosis is solely based on clinical presentation [9, 10]. Sensitivity and
specificity of this case definition is limited by the significant day-to-day symptom variability in stable
COPD, and the variability in symptom perception and reporting by patients [2, 11]. As a result, some of
the events currently approached as exacerbations in fact represent symptom variability in patients with
stable COPD, not associated with short- or long-term adverse outcomes. Furthermore, the diagnostic
criteria of a COPD exacerbation are also fulfilled by other respiratory or non-respiratory presentations (e.g.
cardiovascular diseases) [12]. Inclusion of such events in clinical research studies introduces
nondifferential misclassification bias, thereby reducing the strength of those studies. Moreover, assessment
of the severity of exacerbation is often insufficient, most often relying on clinicians’ decision to administer
antibiotics and/or systematic corticosteroids (moderate) or to admit patients to the hospital (severe
exacerbations) [1, 2]. However, in the absence of prognostic biomarkers these assessments are arbitrary
and inconsistent. Consequently, there is a need to develop accurate diagnostic and prognostic biomarkers
to identify those events associated with adverse short- and long-term sequelae, in the same way that
troponin can differentiate a myocardial infarction from an inconsequential episode of angina in patients
with ischaemic heart disease [13].
Exacerbations are heterogeneous, with different phenotypes, reflecting diverse aetiologies and underlying
mechanisms that require a personalised treatment approach (figure 1) [14]. However, in the absence of
cost-effective, accurate biomarkers able to provide timely clinical characterisation, exacerbations are still
approached as a single disease entity, both in clinical practice, and also in most research studies. This
could cause “dilution” of potential clinical impact of treatments that are effective only in a subgroup of
exacerbations. This is probably the reason why antibiotics and systemic corticosteroids were only found to
have modest effects in unselected exacerbations [15, 16]. Indeed, studies using emerging therapeutic
biomarkers confirm that the impact of these treatments is limited to specific subgroups [17–19].
Shortcomings in clinical characterisation of exacerbations have delayed the introduction of precision
medicine interventions in the management of exacerbations [20].
Challenges in the design and conduct of clinical trials on COPD exacerbations
The acute nature of COPD exacerbations complicates the conduct of clinical research studies evaluating
their management [21–24]. Events qualifying for recruitment cannot be planned and often happen at
inconvenient times. Potential participants are acutely unwell patients who experience severe respiratory
symptoms and stress and are, therefore, less prepared (or capable) to receive information about a research
study or consent to participate. Moreover, numerous clinicians are involved in the management of
inpatient participants and need to be aware of the ongoing trial, prepared to follow the trial procedures
and to adhere to the interventions. Concomitant treatments are difficult to standardise. As a result, such
trials are very expensive, and require specific expertise, infrastructure and large research teams. However,
our colleagues in cardiology, for example, have overcome this hurdle, and in DECODE-NET we believe
this is an area worthy of such commitment of resources.
The design of clinical research studies, and specifically randomised controlled trials (RCTs), on the
management of COPD exacerbations is also complex. Firstly, the heterogeneity of COPD exacerbations
results in a need for more complex clinical trial designs, such as precision medicine trials or adaptive trial
designs [25]. Moreover, the previously mentioned barriers of diagnostic inaccuracy, disease heterogeneity
and lack of accurate therapeutic biomarkers complicates the selection of eligibility criteria that would allow
for the recruitment of a homogeneous population likely to respond to an experimental treatment [11].
Selection of study endpoints is also challenging. Clinical research studies need to evaluate outcome
measures that are important to patients, using standardised outcome definitions to facilitate comparing
and synthesising the results of different studies [26]. In cases of studies evaluating acute events, such as
COPD exacerbations, timing of the evaluation of outcomes is also crucial, as use of different timepoints
could yield different results. A methodological survey revealed that trials of management of COPD
exacerbations conducted during the past decade frequently have significant methodological limitations
[27]. Characteristically, rates of treatment success or failure were only evaluated in 63% of all RCTs, and
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the duration of either symptoms or hospital stay in only 34%. It also revealed a significant heterogeneity in
the definition of outcomes and timing of their evaluation. The DECODE-NET intends to conduct
extensive methodological research to address these challenges.
Vision and first steps of the DECODE-NET
Early career researchers, coupled with more experienced counterparts from over 30 centres from Africa,
America, Asia, Europe and Oceania have already joined the DECODE-NET, including respiratory
physicians, nurses, physiotherapists, physiologists, trialists, methodologists and statisticians. The network
was developed to address the previously described knowledge gaps and methodological challenges, to
promote the conduct of high-quality clinical research focusing on RCTs, and ultimately to improve the
management and outcomes of COPD exacerbations. The DECODE-NET group envisions development of
a global, multidisciplinary, inclusive, independent network that will collectively engage international
expertise and resources. Our network strives for excellence in clinical research design and conduct, in
making best use of the research data and for promotion of a strong educational ethos to support the
development of emerging researchers. The DECODE-NET is an open and collaborative network.
Researchers with interest in COPD exacerbations are welcome to join, by contacting any of the authors of
this editorial. In parallel, we will seek collaboration with other clinical and research networks working on
COPD exacerbations, such as the CICERO (Collaboration In COPD ExaceRbatiOns) ERS Clinical Research
Collaboration [28]. CICERO, through the CATALINA observational study, its flagship project, aims to
further characterise exacerbations clinically and mechanistically. Innovative findings from the CATALINA
study, including much-needed validated diagnostic, prognostic and therapeutic biomarkers, will be fed to
the DECODE-NET and are likely to inform future trial design. We believe the two networks complement
each other and envisage them to have a close, productive collaboration. DECODE-NET will mainly focus
on the conduct of high-quality RCTs, the most rigorous research design that can provide conclusive
evidence of the safety and effectiveness of an intervention by minimising potential biases [29]. Pragmatic
trial designs, testing the effectiveness of treatments applicable to real-life clinical conditions will be
prioritised, to maximise effectiveness [30].
At a recent meeting during the 2019 ERS International Congress we planned several initial research
projects that span across the three main research pillars of the network (figure 2):
Aetiological treatments:
  Antibiotics for bacterial infections
  Systemic corticosteroids for airway eosinophilia
  Antivirals for exacerbations triggered by viruses
  Non-invasive ventilation for T2RF
General measures:
  Oxygen supplementation
  Bronchodilators
  Mucolytics
  Benzodiazepines or opioids
  Evaluation of inhaler technique and adherence
  Prevention of future events
Lung tissue protection/salvage

















Evaluation of impactCharacterisation: Aetiology
FIGURE 1 Characterisation and targeted treatments of COPD exacerbations. Reproduced from [14].
https://doi.org/10.1183/13993003.00627-2020 3
DECODE-NET | A.G. MATHIOUDAKIS ET AL.
1) Methodological research aiming to improve the quality of RCTs. We will develop a core outcome set for
the management of COPD exacerbations. A core outcome set is an agreed minimum set of clinically
important outcomes that should be evaluated in all relevant RCTs and could improve their quality and
comparability [27]. It is based on international, multi-stakeholder consensus. Members of the network
have successfully applied for an ERS task force that is currently undertaking this project. Additional
methodological work will focus on the optimisation of the measurement instruments used to assess the
outcomes of COPD exacerbations in RCTs.
2) Practical implementation of common and standardised assessment of patients with acute exacerbations
of COPD. We will demonstrate that a standardised assessment of the acute patient can be achieved
across several centres, thus demonstrating the ability to carry out large-scale high-quality multicentre
RCTs with sampling material for mechanistic studies and seek diagnostic, prognostic and therapeutic
biomarkers.
3) RCTs aiming to evaluate novel pharmacological and non-pharmacological therapeutic interventions for
COPD exacerbations. The main objective of the DECODE-NET is to conduct multinational RCTs.
Interventions are to be selected through a prioritisation process involving the network’s members and
representatives of the patients and other stakeholders. Moreover, DECODE-NET will provide support,
methodological and clinical expertise and feedback to any of the members conducting relevant RCTs.
The main initial objective of the DECODE-NET will be to secure additional funding through national or
international, public or private funding streams that will allow the conduct of multinational RCTs. Over
the past year we found that all DECODE-NET participants face similar challenges and concerns that can
indeed be addressed more easily through international collaboration. This resulted in enthusiastic, active
involvement of the network’s participants that is considered the best guarantee for success.
The DECODE-NET Investigators: Fekri Abroug, Alvar Agusti, Amy Attaway, Per Bakke, Igor Barjaktarevic,
Konstantinos Bartziokas, Bianca Beghè, Surya P. Bhatt, Andras Bikov, Thomas Bradbury, Guy Brusselle, Robert Burkes,
Cordula Cadus, Marco Contoli, Alexandru Corlateanu, Olga Corlateanu, Gerard Criner, Balazs Csoma, Victoria Dean,
Philip Diaz, Mark T. Dransfield, Carlos Echevarria, Josephin Eklöf, Alexander Emelyanov, Rosa Faner, Gustavo
Fernandez Romero, Nate Gaeckle, Zeineb Hammouda, MeiLan K. Han, Nicholas S. Hill, Peter Horvath, Arturo Huerta,
Anand Iyer, Michael Jacobs, Christine Jenkins, Jens-Ulrik Jensen, Guy Joos, Olga Kharevich, Konstantinos Kostikas,
Jerry A. Krishnan, Stephanie LaBedz, David Lafon, Elena Lapteva, Zsofia Lazar, Jörg D. Leuppi, Carol Liddle, John
Linnell, Alejandra López-Giraldo, Fernando D. Martinez, Fernando J. Martinez, Alexander G. Mathioudakis, Vanessa
McDonald, Takudzwa Mkorombindo, Marilyn Moy, Rune Nielsen, Alberto Papi, Ralph Panos, Trisha Parekh, Ian
Pavord, Victor Pinto-Plata, Robert M. Reed, Jean Rommes, Isabel Saraiva, Galina Sergeeva, Frank C. Sciurba, Dave
Singh, Pradeesh Sivapalan, Daiana Stolz, Charlie Strange, Hao Wang, Fuqiang Wen, Jørgen Vestbo, James M. Wells,
Paula R. Williamson, Janelle Yorke.
The DECODE-NET envisions to improve the management and 
outcomes of COPD exacerbations by promoting global collaboration 











Diagnostic and eligibility criteria
Standardised procedures
Demonstration of multinational RCT feasibility
Practical implementation of common, standardised 
  assessment of patients with acute exacerbations
Standardised sampling for mechanistic and biomarker studies
Prioritised interventions, not necessarily pharmacological
Population defined by treatable traits
State of the art design and patient important outcomes
Embedded mechanistic and methodological studies
Active involvement of early career researchers
Training and accreditation of clinical trial centres
Confidential sound board to discuss projects, receive support      









FIGURE 2 The DECODE-NET vision and objectives.
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DECODE-NET participating centres: Baystate Health, Springfield, Massachusetts, USA; Belarusian Medical Academy of
Postgraduate Education; Birmingham Veterans Affairs Medical Center, Birmingham, Alabama; Cantonal Hospital Basell
and Liestal, Basell, Switzerland; Cleveland Clinic, Cleveland, Ohio, USA; Erasmus Medical Centre, Rotterdam, the
Netherlands; Ghent University Hospital, Ghent, Belgium; Harvard Medical School, Boston, Massachusetts, USA;
Haukeland University Hospital, Bergen, Norway; Herlev-Gentofte Hospital, Hellerup, Denmark; Hospital Clinic,
University of Barcelona, Spain; Hospital Fattouma Bourguina, Monastir, Tunisia; John Hunter Hospital, Hunter New
England Local Health District, Charlestown, New South Wales, Australia; Lewis Katz School of Medicine, Temple
University, Philadelphia, Pennsylvania, USA; Manchester University NHS Foundation Trust, Manchester, UK; Medical
University of North Carolina, Chapel Hill, North Carolina, USA; North-Western Medical University, St. Petersburg,
Russian Federation; State University of Medicine and Pharmacy “Nicolae Testemitanu”, Chisinau, Moldova; Semmelweis
University, Budapest, Hungary; The Christie NHS Foundation Trust, Manchester, UK; The George Institute of Health,
University of New South Wales, Sydney, Australia; The Ohio State University Wexner Medical Center, Columbus, Ohio,
USA; The University of Manchester, Manchester, UK; Tufts Medical Center, Boston, Massachusetts, USA; University
Hospital Basel, Basel, Switzerland; University of Alabama at Birmingham, Birmingham, Arizona, USA; University of
Ioannina School of Medicine, Ioannina, Greece; University of Basel, Basel, Switzerland; University of Bergen, Bergen,
Norway; University of California Los Angeles (UCLA), Los Angeles, California, USA; University of Cincinnati,
Cincinnati, Ohio, USA; University of Copenhagen, Denmark; University of Ferrara, Ferrara, Italy; University of Illinois,
Chicago, Illinois, USA; University of Liverpool, Liverpool, UK; University of Maryland, Baltimore, Maryland, USA;
University of Michigan, Ann Arbor, Michigan, USA; University of Minnesota, Minneapolis, Minnesota, USA; University
of Modena and Reggio Emilia, Modena, Italy; University of Newcastle, Callaghan, New South Wales, Australia;
University of Pittsburgh, Pittsburgh, Pennsylvania, USA; VA Boston Healthcare System, Boston, Massachusetts, USA;
Weil Cornell Medicine, New York, USA; West China Hospital/ West China School of Medicine, Sichuan University,
Chengdu, China.
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